Welcome to our dedicated page for Can-Fite BioPharma news (Ticker: CANF), a resource for investors and traders seeking the latest updates and insights on Can-Fite BioPharma stock.
Can-Fite BioPharma Ltd. reports developments for a clinical-stage biotechnology pipeline of proprietary small-molecule drugs targeting the A3 adenosine receptor (A3AR). Recurring news covers Namodenoson and Piclidenoson across oncology, inflammatory disease, liver disorders, metabolic disease, obesity-related uses, and companion-animal osteoarthritis through its veterinary commercialization relationship.
Company updates also include clinical and regulatory disclosures, patent allowances in multiple jurisdictions, operating and financial results, material agreements, capital-structure actions, and governance matters tied to its American Depositary Shares and ordinary-share voting processes.
Can-Fite (NYSE American: CANF) reported that its Phase 2a open-label study of namodenoson in advanced pancreatic ductal adenocarcinoma met its primary endpoint of safety. The trial enrolled 20 heavily pretreated patients; namodenoson was very well tolerated with no new safety signals identified.
Survival follow-up is ongoing; one-third of patients were alive at data cut-off. Namodenoson holds FDA Orphan Drug Designation for pancreatic cancer and remains under further clinical evaluation.
Can-Fite (NYSE American: CANF) announced a peer-reviewed International Journal of Obesity publication (Feb 17, 2026) showing namodenoson reduced adipocyte proliferation and lipid accumulation in vitro and produced a statistically significant reduction in weight gain in a murine high-fat diet model after four weeks.
According to the company, findings align with prior Phase IIa MASH data showing reduced liver fat and body weight, highlight modulation of adiponectin and multiple metabolic pathways, note a favorable safety profile, and point to potential expansion into the growing obesity treatment market.
Can-Fite (NYSE American: CANF) announced the Canadian Patent Office issued a notice of allowance for Canadian Patent Application No. 3,126,002, covering Namodenoson for use as an anti-obesity therapy.
The allowance adds Canadian IP to existing U.S. and Australian obesity/metabolic patents, cites preclinical fat reduction and a MASH Phase IIa observation of 2.3% weight loss after 3 months with increased adiponectin, and highlights an excellent oral safety profile.
Can-Fite (NYSE American: CANF) reported that a patient with advanced decompensated liver cirrhosis treated with Namodenoson under compassionate use achieved clinical stabilization and subsequently underwent a successful liver transplantation on Feb 5, 2026. The single-case outcome suggests Namodenoson may serve as a supportive bridge to transplant.
The drug is an oral A3 adenosine receptor agonist being evaluated in advanced liver diseases, with prior studies showing a favorable safety profile.
Can-Fite (NYSE American: CANF) completed patient enrollment in its multicenter, open-label Phase 2a study of Namodenoson in advanced pancreatic adenocarcinoma on Jan 20, 2026. The trial evaluates safety (primary endpoint), clinical activity, and pharmacokinetics with oral Namodenoson 25 mg twice daily in continuous 28-day cycles. To date the drug has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer at Davidoff Center, Rabin Medical Center. Can-Fite expects top-line efficacy data in Q3 2026. Namodenoson is a selective A3 adenosine receptor agonist with preclinical anti-tumor activity and has received FDA Orphan Drug Designation for pancreatic cancer.
Can-Fite (NYSE American: CANF) announced that the Brazilian Patent Office granted Patent No. BR112015002697-4 for “Use of an A3 Adenosine Receptor Agonist for the Treatment of Sexual Dysfunction” on Dec. 26, 2025.
The patent provides intellectual‑property protection in Brazil for Can‑Fite’s A3AR agonists for sexual dysfunction, complements the company’s global patent portfolio, and may support future partnering or commercialization opportunities in Latin America. Can‑Fite cites preclinical and clinical data suggesting A3AR activation may modulate signaling related to erectile and sexual function.
Can-Fite (NYSE American: CANF) announced a 1-for-3,000 reverse split of ordinary shares following shareholder approval on November 10, 2025.
The split will be recorded on the Tel-Aviv Stock Exchange on January 2, 2026, with first TASE trading of consolidated shares on January 5, 2026. Concurrently the ADS ratio will change from 1 ADS = 300 ordinary shares to 1 ADS = 2 ordinary shares, effective on the NYSE American on January 5, 2026, requiring an exchange of every 20 ADS for 1 new ADS.
The company will reduce authorized ordinary shares from 42,000,000,000 to 14,000,000 and issue no fractional ordinary shares (rounded up); ADS fractional entitlements will be aggregated and sold by the depositary bank. New CUSIP: 13471N409.
Can-Fite BioPharma (NYSE American: CANF) provided a clinical and financial update on Dec 16, 2025. Key clinical programs: Namodenoson is enrolling a pivotal Phase III in advanced hepatocellular carcinoma (Child-Pugh B7) with an interim analysis ~Q4 2026, a Phase IIb in MASH (following positive Phase IIa published data), and a Phase IIa in pancreatic cancer with data expected Q2 2026. Piclidenoson is enrolling a pivotal Phase III in psoriasis with an interim readout ~Q2 2026. Financials: cash and short-term deposits were $6.45M as of June 30, 2025; the company raised $5M in a July 28, 2025 public offering and $2.2M via ATM in Nov 2025.
Can-Fite BioPharma (NYSE American: CANF) announced that CEO Motti Farbstein will present at NobleCon21 on Wednesday, December 3, 2025 at 12:30 PM ET in Boca Raton, Florida.
The presentation will cover the company's advanced-stage drug development pipeline, including listed trials: Phase III liver cancer, Phase IIa pancreatic cancer, Phase III psoriasis, Phase IIb MASH, and an upcoming Phase II in Lowe syndrome. The CEO will also hold 1x1 investor meetings.
Can-Fite noted existing out-licensing and global distribution agreements worth up to $130 million for pharma indications and up to $325 million for veterinary indications. A high-definition webcast will be available the following day and archived for 90 days on Can-Fite, NobleCon, and Channelchek websites.
Can-Fite (NYSE American: CANF) said it will attend BioFIT 2025 in Strasbourg on Dec 2–3, 2025 to pursue veterinary partnerships for Namodenoson, its Phase III anti-cancer candidate.
The company cites prior BioFIT participation that led to a Piclidenoson veterinary deal with Vetbiolix, an agreement noted as potentially worth an estimated $325 million in royalty revenues. Can-Fite will hold partnering meetings with major animal-health companies including Elanco and Zoetis to explore bringing Namodenoson into veterinary oncology.
Namodenoson has shown strong anti-tumor activity, a reported complete response in a human liver cancer patient, and an excellent safety profile; human trials include a Phase III liver cancer study and a Phase II pancreatic study.